June 25, 2024

Medical Trend

Medical News and Medical Resources

Low-Dose Aspirin: 15% Reduced Risk of Diabetes in Older Adults

Low-Dose Aspirin: 15% Reduced Risk of Diabetes in Older Adults


Low-Dose Aspirin: 15% Reduced Risk of Diabetes in Older Adults.

The latest research findings to be presented at the European Association for the Study of Diabetes (EASD) annual meeting in Hamburg, Germany, from October 2nd to 6th, suggest that taking 100 milligrams of aspirin daily may reduce the risk of developing type 2 diabetes by 15% in individuals aged 65 or older.

Led by Professor Sophia Zoungas from the School of Public Health and Preventive Medicine at Monash University in Melbourne, Australia, the authors emphasize that these findings underscore the need for further exploration of the role of anti-inflammatory medications like aspirin in diabetes prevention.


Low-Dose Aspirin: 15% Reduced Risk of Diabetes in Older Adults.



The impact of aspirin on the incidence of type 2 diabetes in older adults has remained uncertain. This study investigated the randomized treatment effects of low-dose aspirin on diabetes onset and fasting plasma glucose (FPG) levels in older adults. The authors conducted a follow-up study of the ASPREE trial, a double-blind placebo-controlled trial of aspirin, with primary results published in NEJM in 2018. The initial research indicated that aspirin increased the risk of major bleeding in older adults by 38%, with no reduction in cardiovascular disease incidence.

The study recruited community-dwelling residents aged 65 or older with no cardiovascular disease, unrestricted independent limb function, and no dementia. Participants were randomly assigned in a 1:1 ratio to either take 100 milligrams of aspirin or a placebo daily. Diabetes was defined as self-reported diabetes, initiation of glucose-lowering medications, and/or fasting plasma glucose (FPG) levels equal to or exceeding 7.0 mmol/L at annual follow-up visits. Patients with diabetes at baseline were excluded. Computer and statistical models were used to assess the impact of aspirin on diabetes incidence and fasting blood glucose levels.

A total of 16,209 participants were included in the analysis (8,086 on aspirin and 8,123 on placebo). The median follow-up time was 4.7 years, with a total of 995 cases of diabetes recorded (459 in the aspirin group and 536 in the placebo group). Compared to the placebo group, the aspirin group had a 15% lower incidence of diabetes, and the rate of FPG increase was also slightly slower (FPG annual change difference: -0.006 mmol/L).

Professor Zoungas commented, “Aspirin treatment reduces the incidence of diabetes and slows the rate of fasting plasma glucose increase in initially healthy older adults. Given the increasing prevalence of type 2 diabetes in older adults, the potential for anti-inflammatory medications like aspirin to prevent type 2 diabetes or improve blood sugar levels warrants further investigation. Earlier results from the ASPREE trial, published in 2018, showed that aspirin does not prolong healthy independent living but is significantly associated with an increased risk of bleeding, primarily gastrointestinal bleeding. Currently, major prescription guidelines recommend aspirin for older adults only when there are medical indications, such as after a heart attack.”

“While these new findings are intriguing, they do not currently alter clinical recommendations regarding aspirin use in older adults.”

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.